GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
May 23, 2023 07:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will...
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 22, 2023 16:05 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a...
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023 16:05 ET
|
GeneDx Holdings Corp.
Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year Revenue included $22.4 million in whole exome testing,...
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
May 04, 2023 07:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced the availability of its...
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
May 03, 2023 13:06 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification...
GeneDx Announces Reverse Stock Split
April 28, 2023 08:10 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of...
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 18, 2023 16:05 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
April 03, 2023 08:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K....
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
March 20, 2023 08:45 ET
|
GeneDx Holdings Corp.
Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four YearsInitial Data and...
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
March 16, 2023 08:45 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new...